Latest News
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...
Latest News
Weekly News Roundup | 14 September 2026
Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...
Cabozantinib Salt Form Wins FDA Approval Past Malate Patents
A new cabozantinib salt form has cleared the US Food and Drug Administration. Handa Oncology announced on 11 September 2026 that the agency had granted final approval to OMCAZIO (cabozantinib) capsules. The product sits outside the patent estate Exelixis has spent...
Lenacapavir NHS Access Stalls as NICE Rejects Twice-Yearly PrEP
Lenacapavir NHS access for HIV prevention has stalled at the first hurdle. NICE published draft guidance on 9 September 2026. It does not recommend the twice-yearly injection as pre-exposure prophylaxis in England. The draft does not question whether the medicine...
The GLP-1 Divide: Who Gets the Best Weight-Loss Drugs, and Who Pays for It
A patient arrived on my ward recently with a story I have heard so many times it no longer surprises me. Her blood sugar had crept back into the danger zone, her blood pressure was climbing, and the weight she had lost over the previous year was almost all back. The...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Panthera Biopartners Expands European Footprint
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Inside the Science: The Hydrogel Injection Targeting NHS Knee Care
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS A new white paper entitled “Inside the Science: A Major Step Forward for Knee...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
NHS England First in World to Offer Blenrep for Myeloma
Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Weekly News Roundup | 20 April 2026
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Daraxonrasib Phase 3 Trial Results Signal a New Era for Pancreatic Cancer
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
How Can At-Home Diagnostics and AI-Enabled Detection Drive Better Health?
The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier...
Panthera Biopartners Expands European Footprint
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Inside the Science: The Hydrogel Injection Targeting NHS Knee Care
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS A new white paper entitled “Inside the Science: A Major Step Forward for Knee...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
NHS England First in World to Offer Blenrep for Myeloma
Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Weekly News Roundup | 20 April 2026
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Daraxonrasib Phase 3 Trial Results Signal a New Era for Pancreatic Cancer
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
How Can At-Home Diagnostics and AI-Enabled Detection Drive Better Health?
The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier...
Featured Articles
Further News
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The Gut Microbiome and the Future of Human Health
The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Closing the Interventional Gap
The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Transforming Clinical Outsourcing: From Reactive to Predictive Strategy
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.